Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers.
Pure Biologics has been operating on the market since 2010. Its headquarters is located in Wrocław, Poland. Main areas of activity include biotechnology, biological drug discovery and modern therapeutic solutions based on antibodies and aptamers. In two key projects the Company has completed all steps in the drug development process – from target selection and validation to preclinical studies – and has directed them to phase 0 clinical trials.
In 2022 Pure Biologics has established a special purpose vehicle Doto Medical – focused on the accelerated development and commercialization of the key aptamer project in its portfolio – PB103, implemented in cooperation with the established on the biomedical market Dutch company Relitech BV. The project aims to develop a medical device for patients with Chronic Kidney Disease (CKD). At the same time, the company established cooperation with a renowned transaction advisor, Clairfield Partners.
Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of autoimmune, neurodegenerative and rare diseases. It is a total of a dozen projects, including five key projects in which we use antibody and aptamer technologies to develop molecules with therapeutic potential.
Our projects are a continual source of novel ideas, solutions, and interesting scientific results, which we translate into new therapies for patients in greatest need. Uniqueness and innovation of these results are best evidenced by original publications and other studies, which we regularly present at conferences and scientific seminars.
We bet on stable and balanced development in all key operation areas – our therapeutic portfolio, scientific and business expertise, infrastructure and networking. Our plans envisage achieving financial independence and profits by commercializing therapeutic candidates, allowing us to pursue our next, advanced ideas.
